Pneumococcal vaccination may reduce the risk for pneumonia-related morbidity and mortality among patients with immune-mediated inflammatory diseases.

At the highest dose tested, Vaxcyte’s shot elicited a stronger immune response against 18 of the 20 strains compared with ...

Pneumococcal bacteria are present in the normal microbiome of the nose of many children and adults. In certain circumstances, ...

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

Vaxcyte Inc.’s stock soared 42% Tuesday, after the vaccine maker reported positive results from an early-stage trial of its ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

More than 23,000 Cuban children have so far been vaccinated against pneumococcus using the drug Pneumosil 10-valent, which ...

Pneumococcal Vaccine Market” from 2024-2034 with covered segments By Vaccine Type (Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Va ...

Vaxcyte’s market potential is driven by $13.3B TAM in pneumococcal vaccine market, with potential FDA approval by late 2026 ...

A growing number of U.S. adults are hesitant to get recommended vaccines this fall, a new survey found. Doctors discuss potential reasons and why it could be concerning.

However, increase in disease-causing or colonizing pneumococcal strains with intermediate resistance due to selective pressure can become a clinical concern. Therefore, changing trends should be ...